AbbVie Reports Q1 2026 Earnings Results
AbbVie (ABBV) reported Q1 2026 earnings with adjusted EPS of $2.65, exceeding guidance, and total net revenues of $15 billion, up 12.4%. The company raised its full-year adjusted EPS guidance to $14.08 to $14.28. Key products like Skyrizi and Rinvoq saw strong growth, while HUMIRA and IMBRUVICA faced challenges from biosimilars and pricing pressures.
Tickers: $ABBV
Topics: Earnings Financial Performance Guidance Revenue Stock Price Movement